Rockwell Medical, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. Rockwell develops, manufactures, and distributes hemodialysis products; dialysis concentrates are its core business.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $23.8 million | $18.7 million | $61.5 million | $53.5 million |
| Gross profit / margin | $2.2 million / 9% | $0.8 million / 4% | $5.8 million / 9% | $1.7 million / 3% |
| Operating loss | $1.7 million | $3.7 million | $6.1 million | $14.8 million |
| Net loss | $1.9 million | $4.2 million | $6.9 million | $16.3 million |
| Loss per share | $0.07 | $0.23 | $0.32 | $1.26 |
Q3 sales grew 27%; nine-month sales grew 15%. Q3 gross margin improved to 9% from 4%; nine-month gross margin improved to 9% from 3%. The company remained loss-making.
- Cash and liquidity: At September 30, cash and cash equivalents were $7.8 million and available-for-sale investments were $4.0 million, totaling $11.7 million. Working capital was $6.8 million.
- Cash flows: Nine-month operating cash use was $9.4 million, versus $16.8 million in 2022; investing cash use was $5.1 million; financing cash provided was $12.1 million. Ending cash was $7.8 million, down $2.3 million from year-end 2022.
- Debt: Innovatus term-loan principal was $9.5 million at September 30 (carrying amount, net of issuance costs and discount, approximately $9.0 million). The loan matures in March 2025; its effective interest rate was 12.5%. The company reported covenant compliance.
- Balance sheet: Total assets were $52.6 million and total liabilities $31.1 million. The company recorded a $10.9 million customer-relationships intangible asset from the Evoqua acquisition.
Material changes and notable items
- The July 10 Evoqua asset acquisition added customer relationships, equipment, and inventory for $17.4 million total consideration: approximately $12.4 million paid at closing and two $2.5 million deferred payments. The acquired customer relationships contributed $3.4 million of Q3 revenue.
- Q3 revenue also included approximately $2.2 million of accelerated Wanbang license revenue after the partner ended Triferic development in China. A $1.1 million reserve was recorded against related Triferic inventory.
- DaVita product pricing increased effective September 1 under an amended agreement, which also provides for a one-time payment on or after December 1; the filing does not state its amount. DaVita represented approximately 50% of sales in both the quarter and nine-month period.
- Other sales growth reflected the direct distribution model after Rockwell reacquired rights from Baxter, new customers, and pricing changes. Management cited lower distribution costs as a contributor to improved gross profit.
- Operating expenses declined year over year, particularly R&D and G&A. R&D spending fell partly because the FPC home-infusion program was paused; severance represented approximately 44% of nine-month R&D expense.
- Common shares outstanding increased to 28.5 million from 12.2 million at December 31, 2022, including issuance connected with warrant exercises. Armistice’s exercise of a warrant generated approximately $13.8 million in July.
- Rockwell recalculated 2022 loss-per-share figures to include certain pre-funded warrants in weighted-average shares. It said the change was not material to previously issued financial statements.
Outlook, risks, and contingencies
Management believes available working capital is sufficient for operating needs for at least 12 months from the filing date, but says additional capital may be needed. Potential funding includes the ATM facility or other financing; availability and terms are not assured. DaVita-related terms restrict certain additional debt unless DaVita consents. Management is pursuing customer growth and cost containment; the filing provides no quantified earnings or revenue guidance.
- The DaVita agreement expires December 31, 2024. DaVita may extend it through 2025 at its discretion. Rockwell warns that failure to reach economically acceptable renewal terms could cost it approximately half of current concentrates volume and materially harm results.
- Triferic commercialization in the U.S. has been discontinued; China development ended after the trial did not achieve its main efficacy results. India, Peru, and Chile development work is on hold. The company continues to support other international partners and evaluate FPC opportunities.
- Management cited uncertain capital and credit markets, inflation, interest rates, supply-chain and geopolitical risks as potential pressures on liquidity; it could not quantify their effects.
- Routine legal proceedings are not expected to have a material effect. Management reported effective disclosure controls as of September 30, 2023 and no material change in internal control over financial reporting.
Most important facts for investors to verify
- Whether improved gross margins and customer additions persist after acquisition-related and accelerated license revenue effects.
- DaVita’s purchasing volumes, the terms and amount of its one-time payment, and renewal or extension prospects before the December 2024 expiration.
- Cash burn, working-capital needs, and the company’s ability to fund operations and meet debt and deferred acquisition payments without unfavorable or dilutive financing.
- Integration and contribution of the Evoqua assets, including the acquired customer relationships and contract manufacturing arrangements.
- Further developments in Triferic’s international programs and any additional inventory reserves or impairment-related charges.
- Share-count and potential dilution effects from outstanding warrants, options, restricted stock, and convertible preferred stock.